ArticleMolecular biology reports2026
Expression of adenosine A1, A2A, A2B, and A3 receptors in ovarian cancer: their clinical potential in diagnosis and prognosis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have emphasized the role of adenosine receptors (ADORs) in the malignant biological behaviors. Therefore, the expression and clinical significance of four subtypes of ADORs (ADORA1, ADORA2A, ADORA2B, and ADORA3) in ovarian tumors were analyzed. METHODS AND
resultsThe expression of ADORs in 24 pairs of ovarian tumor tissues and adjacent non-tumor tissues was measured by quantitative real-time PCR. The correlations between the investigated parameters and clinicopathological features were statistically tested. The diagnostic accuracy of ADORs was assessed using receiver operating characteristic curve analysis. Kaplan-Meier method was used to estimate the influence of ADORs expression on the prognosis of patients. Ovarian tumors showed higher expression of ADORA2A (1.5-fold), ADORA2B (2.2-fold), and ADORA3 (2.3-fold), but not ADORA1, compared to normal tissues. High expression of ADORA1 and ADORA2A was associated with younger age (≤ 48.5 years; P = 0.034) and clinical stage III-IV (P = 0.050), respectively. ADORA2B also showed moderate accuracy in ovarian tumors diagnosis (P = 0.001). Survival analyses further demonstrated that high expression of ADORA1 (P = 0.012) and ADORA2B (P = 0.027) was correlated with worse overall survival. Moreover, high ADORA3 expression (P = 0.042) was associated with poor post-progression survival.
conclusionsOur results demonstrated that adenosine A2A, A2B, and A3 receptors were differentially expressed between ovarian tumors and paired non-tumor tissues, and that ADORs may be clinically useful biomarkers for diagnosis and outcome prediction in ovarian cancer.
Indexed as
Identifiers
42234312What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.